Jonathan Rubin - Dec 22, 2023 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role
Sr. VP, Chief Medical Officer
Signature
/s/ Timothy C. Dec, as attorney-in-fact
Stock symbol
SUPN
Transactions as of
Dec 22, 2023
Transactions value $
-$5,643
Form type
4
Date filed
12/26/2023, 05:01 PM
Previous filing
Dec 18, 2023
Next filing
Feb 26, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SUPN Common Stock Options Exercise $0 +600 +21.07% $0.00 3.45K Dec 22, 2023 Direct F1
transaction SUPN Common Stock Tax liability -$5.64K -204 -5.92% $27.66 3.24K Dec 22, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SUPN Performance Share Unit Options Exercise $0 -600 -100% $0.00* 0 Dec 22, 2023 Common Stock 600 $0.00 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 22, 2022.
F2 Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.
F3 On February 22, 2022, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2022.